Interleukin-2 (IL-2) was first identified in 1976 and has since been demonstrated to effectively enhance the production of T lymphocytes in large quantities when administered to individuals with metastatic cancer [133]. The gene discussed is IL2; the disease is metastatic malignant neoplasm.